Assert-IQ vs prolaio eVO2peak Module
AI Verdict
Choose Assert-IQ if…
Choose Assert-IQ if your clinical practice requires long-term, continuous, and highly accurate monitoring for the definitive diagnosis and management of suspected heart rhythm disorders. This system is ideal for patients needing extended cardiac event detection and remote oversight through a minimally invasive insertable device.
View Assert-IQ →Choose prolaio eVO2peak Module if…
Choose prolaio eVO2peak Module if you need to estimate peak oxygen consumption (eVO2peak) using real-world patient data from qualified third-party wearable medical sensors for cardiovascular research or as an adjunctive aid in clinical evaluation. This software is best suited for assessing cardiovascular fitness and risk without requiring an implanted device.
View prolaio eVO2peak Module →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Assert-IQ | prolaio eVO2peak Module |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Subcutaneously implanted device with mobile app connectivity | Cloud-based (software-only, processes remote sensor data) |
| FDA Status | Cleared AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Assert-IQTool A, Assert-IQ, involves a minimally invasive insertion but then offers long-term, passive monitoring for the patient and proactive alerts for clinicians, streamlining ongoing use. Tool B, prolaio eVO2peak Module, is software-only but relies on patients consistently wearing and managing third-party sensors, which could introduce more patient-side friction and management overhead. Therefore, Tool A wins for its 'set it and forget it' patient experience and direct data delivery for clinicians.
Clinical Value
Assert-IQTool A, Assert-IQ, provides long-term, continuous cardiac monitoring and advanced arrhythmia detection, directly addressing the diagnosis and management of suspected heart rhythm disorders. Tool B, prolaio eVO2peak Module, estimates eVO2peak, a valuable biomarker for cardiovascular health and risk assessment. While both offer significant clinical value, Tool A's direct, continuous arrhythmia detection addresses a more immediate and often challenging diagnostic problem for specific cardiac conditions.
Pricing & Value
TieBoth tools require direct contact for institutional or enterprise pricing and do not offer transparent pricing or free trials. Without specific cost details or comparative value propositions, it is impossible to determine a winner. Therefore, based on the available information, this dimension is a tie.
Enterprise Readiness
Assert-IQAbbott Medical (Tool A) is a well-established, global medical device company with extensive experience deploying and supporting solutions in large health systems. While Tool B is FDA-cleared and HIPAA compliant, Abbott's sheer size, market presence, and hybrid deployment option provide a stronger indication of robust enterprise readiness and support infrastructure.
Innovation
prolaio eVO2peak ModuleTool A offers significant advancements in ICM longevity (up to 6 years) and remote monitoring capabilities. However, Tool B's innovation lies in its software-only approach, utilizing a locked deep-learning model to estimate a complex physiological parameter (eVO2peak) from diverse real-world data collected from third-party FDA-cleared wearable sensors. This integration of AI with external, multi-modal sensor data for an FDA-cleared clinical aid represents a more novel and cutting-edge application of AI in healthcare.
Support & Docs
Assert-IQAbbott Medical (Tool A) is a large, established global company known for its comprehensive support, training, and documentation resources for its medical devices. While no specific details are provided for either tool, the reputation and infrastructure of Abbott suggest a more robust and extensive support ecosystem compared to a potentially smaller 'clinical intelligence company' like Prolaio (Tool B).
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Assert-IQ | prolaio eVO2peak Module |
|---|---|---|
| Product Name | Assert-IQ | prolaio eVO2peak Module |
| Company | Abbott Medical | Prolaio |
| Primary Function | Long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders. | Estimates peak oxygen consumption using real-world patient data for cardiovascular research and care. |
| Key Data Inputs/Outputs | Inputs: Cardiac electrical activity; Outputs: Arrhythmia detection, proactive clinician alerts, patient symptom logging. | Inputs: Demographic data, single-lead ECG, and triaxial accelerometry from qualified third-party FDA-cleared wearable medical sensors; Outputs: Estimated peak oxygen consumption (eVO2peak). |
| Target Medical Specialties | Cardiology, Internal Medicine | Cardiology, Physical Medicine & Rehab, Sports Medicine |
| Data Export Capability | Yes | Not specified |
Videos
Demos, reviews, and walkthroughs featuring Assert-IQ and prolaio eVO2peak Module.